ETOP

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression

Retrieved on: 
Thursday, March 17, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, EORTC, ETOP, Lung Cancer, Merck’s Research in Lung Cancer, Merck’s Early-Stage Cancer Clinical Program, Merck, EORTC, ETOP, LUNG CANCER, MERCK’S RESEARCH IN LUNG CANCER, MERCK’S EARLY-STAGE CANCER CLINICAL PROGRAM, MERCK

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 82% of all cases.

Key Points: 
  • Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 82% of all cases.
  • In the U.S., the overall five-year survival rate for patients diagnosed with lung cancer is 24%, a 14% improvement over the last five years.
  • Among Mercks research efforts are trials focused on evaluating KEYTRUDA in earlier stages of lung cancer as well as identifying new combinations and coformulations with KEYTRUDA.
  • Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA.

Merck’s KEYTRUDA® (pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients With Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression

Retrieved on: 
Monday, January 10, 2022
Oncology, Medical Supplies, Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, KEYNOTE-091/EORTC-1416-LCG – PEARLS, EORTC, ETOP, Lung Cancer, Merck’s Early-Stage Cancer Clinical Program, Merck, KEYNOTE-091/EORTC-1416-LCG – PEARLS, EORTC, ETOP, LUNG CANCER, MERCK’S EARLY-STAGE CANCER CLINICAL PROGRAM, MERCK

We are encouraged by these results supporting the potential role of KEYTRUDA in stage IB-IIIA non-small cell lung cancer.

Key Points: 
  • We are encouraged by these results supporting the potential role of KEYTRUDA in stage IB-IIIA non-small cell lung cancer.
  • The results from KEYNOTE-091 are a first for KEYTRUDA in the adjuvant treatment setting in patients with stage IB-IIIA NSCLC.
  • Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all cases.
  • Selected KEYTRUDA (pembrolizumab) Indications in the U.S.
    KEYTRUDA is indicated for the treatment of patients with unresectable or metastatic melanoma.